Mitochondrial Dysfunction is a Key Driver of Acute Kidney Injury Pathophysiology
As highlighted in Nature Reviews Nephrology by Prof. John Kellum (Center for Critical Care Nephrology, Univ. of Pittsburgh) in his…
Targeting NAD+ Synthesis via inhibition of ACMSD to prevent NAFLD and AKI
Publishing in Nature, scientists lead Johan Auwerx at EPFL (Lausanne) and Roberto Pellicciari at TES Pharma have found a new…
De novo NAD+ synthesis enhances mitochondrial function and improves health
TES Pharma announces the publication of a Nature paper “De novo NAD+ synthesis enhances mitochondrial function and improves health” (DOI: 10.1038/s41586-018-0645-6)…
POR FESR 2014-2020 Regione Umbria
Progetto finanziato dalla Regione Umbria nel quadro del “Bando a sostegno dei progetti complessi di ricerca & sviluppo - POR FESR 2014-2020”.…
α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Inhibitors as Novel Modulators of NAD+ Biosynthesis
TES Pharma announces the publication of a Journal of Medicinal Chemistry paper “α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of…
Umbria ERDF Project
TES announces the successful awarding of a European Regional Development Fund, Umbria project, "Integrated platform for innovative drug research and…
TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) Announce R&D Collaboration on Small Molecule Therapies for Metabolic Disorders and Age-Related Diseases
TES Pharma and EPFL announce a new research and development collaboration on novel small molecule modulators of the kynurenine pathway…